Myeloma Patients Europe (MPE) held the first Myeloma CAB
Based on the proven CML Advocates Network and ECAB model implemented by the HIV patient community and European AIDS Treatment Group (EATG), MPE held the first myeloma CAB from 11 to 13 May in Warsaw, Poland, to promote best-in-class myeloma research as well as the harmonisation of good clinical practice, standard of care and access to best available myeloma therapies and diagnostic tools. A range of topics were discussed in these successful meetings between sponsors and advocates such as innovative therapies, access to myeloma drugs in Europe and patient involvement in medicines research and development.
Survey on myeloma patient information needs
Myeloma Patients Europe (MPE) and Amgen are launching a survey for European myeloma patients to understand their information needs. If you are a myeloma patient living in the UK, and have received at least one prior treatment or are currently on your first treatment, MPE would be very grateful if you would take the time to complete the anonymous survey. The survey will be run in 12 European countries, however, at this stage we need responses from UK patients only.
MPE webinar on CAR-T cell treatment in myeloma
MPE held a webinar on CAR-T cell treatment with the aim of providing an overview of CAR-T cell treatment in myeloma and to discuss some of the advantages and challenges the myeloma community faces in bringing this treatment to market. The talk was given by Dr Matteo Carrabba, Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan (Italy).